imaging questions in ovarian cancer susanna i. lee, md, phd
TRANSCRIPT
![Page 1: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/1.jpg)
Imaging Questions in Ovarian Cancer
Susanna I. Lee, MD, PhD
![Page 2: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/2.jpg)
Emerging Technologies
• PET-CT
• Perfusion imaging– Dynamic contrast enhanced CT (DCE-CT)
– Dynamic contrast enhanced MRI (DCE MRI)
• Nodal imaging– Ultrasmall superparamagnetic iron oxide (USPIO) MRI
– Diffusion weighted imaging (DWI) MRI
• Percutaneous tumor ablation
![Page 3: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/3.jpg)
• 22,975 studies from 1,178 centers over 1 year
• 15% patients with gynecologic cancers– 2,096 ovarian
– 1,198 uterine corpus
– 434 cervix
• Query referring physician on intended patient management before and after PET-CT
![Page 4: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/4.jpg)
PET Impact on Management
Hillner BE et al. J Clin Oncol 2008. 26:2155
![Page 5: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/5.jpg)
PET-CT in Recurrence
no treatment treatment
![Page 6: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/6.jpg)
PET-CT in Recurrence
surgery chemotherapy
![Page 7: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/7.jpg)
PET-CT in Recurrence
CT alone PET-CT
Sensitivity 92% 97%
Specificity 60% 80%
Kappa 0.29 0.63
Sebastian S et al. Abdom Imaging 2008. 33:112
• 53 patients with epithelial ovarian cancer
• Concurrent diagnostic CT and PET-CT scans
![Page 8: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/8.jpg)
Emerging Technologies
• PET-CT
• Perfusion imaging– Dynamic contrast enhanced CT (DCE-CT)
– Dynamic contrast enhanced MRI (DCE MRI)
• Nodal imaging– Ultrasmall superparamagnetic iron oxide (USPIO) MRI
– Diffusion weighted imaging (DWI) MRI
• Percutaneous tumor ablation
![Page 9: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/9.jpg)
DCE MRI Tracer Kinetic Model
Ktrans
ep= Ktrans/e
e=
Volume transfer constant
Flux rate constant
Tofts PS et al. J Magn Reson Imaging 1999. 10:223
![Page 10: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/10.jpg)
DCE MRI As a Biomarker
• Correlate with pathologic prognostic indicators– Tumor grade, microvessel density, VEGF expression
• Predict clinical response to therapy– Anti-VEGF antibody, tyrosine kinase inhibitor
• Prospectively acquired DCE MRI databases with corresponding clinical outcome– ACRIN 6657/CALGB 150007 – neoadjuvant breast cancer– ACRIN 6677/RTOG0265 – recurrent glioblastoma
![Page 11: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/11.jpg)
Neoadjuvant Breast Cancer
Hylton N. J Clin Oncol 2006. 24:3293
DCE MRI
SER map
pre post 1 cycle post chemo
![Page 12: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/12.jpg)
Emerging Technologies
• PET-CT
• Perfusion imaging– Dynamic contrast enhanced CT (DCE-CT)
– Dynamic contrast enhanced MRI (DCE MRI)
• Nodal imaging– Ultrasmall superparamagnetic iron oxide (USPIO) MRI
– Diffusion weighted imaging (DWI) MRI
• Percutaneous tumor ablation
![Page 13: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/13.jpg)
USPIO MRI
• Paramagnetic core in dextran
• Half life ~25-30 h
• Nanoparticles dark on T2*
• Macrophage accumulation– Normal nodes = dark
– Tumor replaced nodes = bright
Harisinghani MG et. al. N Eng J Med 2003. 348: 2491
![Page 14: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/14.jpg)
USPIO MRI Endometrial Cancer
benign
malignant
![Page 15: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/15.jpg)
USPIO MRI for Nodal Metastases• 631 patients, 3004 nodes with histology
• Summary ROC for per lymph node data
AUC = 0.96AUC = 0.84
Will O et al. Lancet Oncol 2005. 7:52
![Page 16: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/16.jpg)
What About the Small Nodes?
Any size <10 mm
Unenhanced MRI 63% NA
USPIO MRI 88% 70%
PET-CT (cervical ca)* 72% 37%
PET-CT (endometrial ca)^ 53% 40%
*Sironi S et al. Radiology 2006. 238:272^ Kitajima K et al. Am J Roentgenol 2008. 190:1652
![Page 17: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/17.jpg)
USPIO and Small NodesEndometrial ca with 5 mm node
USPIO PET
![Page 18: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/18.jpg)
Percutaneous Tumor Ablation
• Thermal – frictional heating– Radiofrequency (460 kHz)
– Microwave (900-2450 MHz)
• Cryo – freeze thaw cycles
• High intensity focused ultrasound (HIFU)– Acoustic lens to focus ultrasound for power deposition
– Thermonecrosis
– No applicator tract
![Page 19: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/19.jpg)
Radiofrequency Ablation
• Radiofrequency generator 60-250 W
• Coagulation necrosis 55-100oC
GroundingPad
Power Source
![Page 20: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/20.jpg)
Radiofrequency Ablation• Indications– Medically inoperable patients or bridge to transplant
– Liver – hepatocellular carcinoma, colon cancer
– Kidney – renal cell ca
– Lung – NSCLC, metastases
• Lesion selection criteria– Percutaneous approach available
– < 5.5 cm
– Adjacent structures
– Heat sink effect
![Page 21: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/21.jpg)
Clear Cell Ovary Recurrence
![Page 22: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/22.jpg)
Radiofrequency Ablation
hydrodissection ablation
![Page 23: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/23.jpg)
Followup PET-CT1 month 1 year
![Page 24: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/24.jpg)
High Grade Muellerian AblationPre-RF RF
![Page 25: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/25.jpg)
Three Year Followup3 months 3 years
![Page 26: Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD](https://reader035.vdocuments.us/reader035/viewer/2022081603/56649e7b5503460f94b7cb41/html5/thumbnails/26.jpg)